DB:0IK

Stock Analysis Report

Executive Summary

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has NGM Biopharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

DB:0IK

1.9%

DE Pharmaceuticals

0.8%

DE Market


1 Year Return

n/a

DB:0IK

-10.6%

DE Pharmaceuticals

-10.9%

DE Market

No trading data on 0IK.

No trading data on 0IK.


Share holder returns

0IKIndustryMarket
7 Day0%1.9%0.8%
30 Day-0.02%5.5%-5.3%
90 Dayn/a12.4%-3.2%
1 Yearn/a-7.5%-10.6%-8.1%-10.9%
3 Yearn/a-10.8%-18.4%10.4%0.9%
5 Yearn/a31.5%9.9%25.5%8.1%

Price Volatility Vs. Market

How volatile is NGM Biopharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is NGM Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

3.31x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for NGM Biopharmaceuticals to establish if it is available at moderate discount.

Unable to calculate intrinsic value for NGM Biopharmaceuticals to establish if it is available at substantial discount.


Price Based on Earnings

NGM Biopharmaceuticals is loss making, we can't compare its value to the DE Pharmaceuticals industry average.

NGM Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for NGM Biopharmaceuticals, we can't assess if its growth is good value.


Price Based on Value of Assets

NGM Biopharmaceuticals is overvalued based on assets compared to the DE Pharmaceuticals industry average.


Next Steps

Future Growth

How is NGM Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

-30.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

NGM Biopharmaceuticals's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.

NGM Biopharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.

NGM Biopharmaceuticals's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.

Unable to compare NGM Biopharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.

Unable to compare NGM Biopharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if NGM Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has NGM Biopharmaceuticals performed over the past 5 years?

21.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

NGM Biopharmaceuticals does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.

Unable to compare NGM Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare NGM Biopharmaceuticals's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if NGM Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if NGM Biopharmaceuticals has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if NGM Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is NGM Biopharmaceuticals's financial position?


Financial Position Analysis

NGM Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

NGM Biopharmaceuticals's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

NGM Biopharmaceuticals has no debt.

NGM Biopharmaceuticals has not taken on any debt in the past 5 years.


Balance Sheet

Low level of unsold assets.

NGM Biopharmaceuticals has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

NGM Biopharmaceuticals has sufficient cash runway for more than 3 years based on current free cash flow.

NGM Biopharmaceuticals has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -9.3% each year.


Next Steps

Dividend

What is NGM Biopharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate NGM Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate NGM Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as NGM Biopharmaceuticals has not reported any payouts.

Unable to verify if NGM Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as NGM Biopharmaceuticals has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of NGM Biopharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.


Next Steps

Management

What is the CEO of NGM Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

0.9yrs

Average management tenure


CEO

David Woodhouse (48yo)

0.9yrs

Tenure

0

Dr. David J. Woodhouse, Ph.D. had served as the Chief Financial Officer of NGM Biopharmaceuticals, Inc. since March 2, 2015 until September 2018 and serves as its Chief Executive Officer, Acting Chief Fina ...


Management Age and Tenure

0.9yrs

Average Tenure

49yo

Average Age

The average tenure for the NGM Biopharmaceuticals management team is less than 2 years, this suggests a new team.


Board Age and Tenure

10.5yrs

Average Tenure

59yo

Average Age

The average tenure for the NGM Biopharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$2,804,03009 Aug 19
Ponoi Capital
EntityCompany
Shares224,664
Max PriceUS$12.48
BuyUS$76,57207 Aug 19
Ponoi Capital
EntityCompany
Shares6,134
Max PriceUS$12.48
BuyUS$55,13805 Aug 19
Ponoi Capital
EntityCompany
Shares4,382
Max PriceUS$12.59
BuyUS$344,45531 Jul 19
Ponoi Capital
EntityCompany
Shares28,056
Max PriceUS$12.48
BuyUS$1,090,33826 Jul 19
Ponoi Capital
EntityCompany
Shares89,866
Max PriceUS$12.23
BuyUS$819,23323 Jul 19
Ponoi Capital
EntityCompany
Shares67,742
Max PriceUS$12.54
BuyUS$245,72717 Jul 19
Ponoi Capital
EntityCompany
Shares20,088
Max PriceUS$12.36
BuyUS$393,08715 Jul 19
Ponoi Capital
EntityCompany
Shares31,884
Max PriceUS$12.33
BuyUS$147,94026 Jun 19
Ponoi Capital
EntityCompany
Shares12,240
Max PriceUS$12.09
BuyUS$422,03621 Jun 19
Ponoi Capital
EntityCompany
Shares34,377
Max PriceUS$12.39
BuyUS$372,64414 Jun 19
Ponoi Capital
EntityCompany
Shares29,760
Max PriceUS$12.59
BuyUS$285,34111 Jun 19
Ponoi Capital
EntityCompany
Shares23,500
Max PriceUS$12.22
BuyUS$298,98806 Jun 19
Ponoi Capital
EntityCompany
Shares25,200
Max PriceUS$11.87
BuyUS$604,19322 May 19
Ponoi Capital
EntityCompany
Shares50,000
Max PriceUS$12.08
BuyUS$220,80413 May 19
Ponoi Capital
EntityCompany
Shares17,923
Max PriceUS$12.32
BuyUS$718,58809 May 19
Ponoi Capital
EntityCompany
Shares57,000
Max PriceUS$12.61
BuyUS$284,19210 Apr 19
Peter Svennilson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares20,000
Max PriceUS$14.21
BuyUS$26,643,00010 Apr 19
Ponoi Capital
EntityCompany
Shares1,875,000
Max PriceUS$14.21
BuyUS$213,14410 Apr 19
Timothy Kutzkey
EntityIndividual
Shares15,000
Max PriceUS$14.21
BuyUS$99,46710 Apr 19
Suzanne Hooper
EntityIndividual
Shares7,000
Max PriceUS$14.21
BuyUS$58,567,46709 Apr 19
Merck & Co., Inc.
EntityCompany
Shares4,121,683
Max PriceUS$14.21

Ownership Breakdown


Management Team

  • Bill Rieflin (59yo)

    Executive Chairman of the Board of Directors

    • Tenure: 0.9yrs
    • Compensation: US$1.81m
  • Jin-Long Chen (56yo)

    Founder

    • Tenure: 11.6yrs
    • Compensation: US$1.65m
  • Alex DePaoli

    Chief Translational Officer & Senior VP

    • Tenure: 0.0yrs
  • Hsiao Lieu (49yo)

    Chief Medical Officer & Senior VP

    • Tenure: 0.4yrs
  • Hui Tian

    Senior Vice President of Research

    • Tenure: 0.0yrs
  • Aetna Trombley (40yo)

    President & COO

    • Tenure: 0.9yrs
  • David Shen

    Senior Vice President of Biologics and CMC

    • Tenure: 0.0yrs
  • David Woodhouse (48yo)

    CEO, Acting CFO & Director

    • Tenure: 0.9yrs

Board Members

  • Mark Leschly (50yo)

    Director

    • Tenure: 11.6yrs
  • Mac Tichenor (64yo)

    Director

    • Tenure: 9.4yrs
  • David Goeddel (67yo)

    Lead Independent Director

    • Tenure: 0.9yrs
  • Bill Rieflin (59yo)

    Executive Chairman of the Board of Directors

    • Tenure: 0.9yrs
    • Compensation: US$1.81m
  • Michael Brown (78yo)

    Chairman of the Scientific Advisory Board

    • Tenure: 0.0yrs
  • Joseph Goldstein (79yo)

    Member of the Scientific Advisory Board

    • Tenure: 0.0yrs
  • David Schnell (59yo)

    Director

    • Tenure: 11.6yrs
  • Peter Svennilson (57yo)

    Director

    • Tenure: 11.6yrs
  • Jin-Long Chen (56yo)

    Founder

    • Tenure: 11.6yrs
    • Compensation: US$1.65m
  • David Woodhouse (48yo)

    CEO, Acting CFO & Director

    • Tenure: 0.9yrs

Company Information

NGM Biopharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: NGM Biopharmaceuticals, Inc.
  • Ticker: 0IK
  • Exchange: DB
  • Founded: 2007
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.145b
  • Listing Market Cap: US$1.028b
  • Shares outstanding: 65.90m
  • Website: https://www.ngmbio.com

Number of Employees


Location

  • NGM Biopharmaceuticals, Inc.
  • 333 Oyster Point Boulevard
  • South San Francisco
  • California
  • 94080
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NGMNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDApr 2019
0IKDB (Deutsche Boerse AG)YesCommon StockDEEURApr 2019

Biography

NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthal ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/25 22:38
End of Day Share Price2019/08/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.